A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.